Full-Time

Senior Research & Development Program Manager

Posted on 3/12/2025

Absci

Absci

51-200 employees

Biotech company specializing in protein production

Compensation Overview

$106k - $150kAnnually

+ Equity Package + Bonus

Senior

Vancouver, WA, USA

Category
Project Management
Business & Strategy
Requirements
  • Bachelor’s degree in a science-related field with 5+ years of experience in a biotech-related field or equivalent technical work experience; or a Master’s degree and 3+ years; or a PhD Degree and 1+ years.
  • Working knowledge of project management software (MS Project, SmartSheet, etc.)
  • Familiar with workflows involving protein engineering, cloning, high-throughput screening, protein purification, and/or analytical chemistry
  • Proven experience with Change Management and Conflict Resolution with a proactive mindset
  • Demonstrated commitment to Absci's core values.
Responsibilities
  • Support corporate strategy and portfolio strategy by safeguarding success of highly cross-functional Drug Creation pipeline programs and communicating effectively with leadership about risks, costs, and opportunities.
  • Facilitate cross-functional discussion to align objectives, scope and pressure-test plans, surface and mitigate risk, and drive decision making.
  • Simultaneously balance activities between multiple projects of various scopes.
  • Drive execution of or cross-functional programs by planning activities, tracking activities, and holding stakeholders accountable for project tasks and deadlines.
  • Estimate and manage the costs and time to complete the work within budget and timeline using project management software.
  • Identify, assess, prioritize & manage project-related risks and clearly present solutions that link directly to the key program objectives.
  • Define the project team's structure and culture and use technology to ensure essential communication between groups in business processes and during experimental handoffs.
  • Work with stakeholders and scientific leadership to understand failure modes and implement corrective actions while working to build a system where operational activities are increasingly automatic and seamless.
Desired Qualifications
  • Project management training
  • In-depth or hands-on experience with SmartSheet or other project management software
  • Any in-depth experience in one (or more) areas in the workflows mentioned.

AbSci improves protein expression and biomanufacturing in the biotech industry with its advanced platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system for precise control over protein production. Its standout product, SoluPure, is a chromatography-free purification method that simplifies and speeds up the protein purification process. AbSci sets itself apart from competitors by offering proprietary technologies that enhance drug discovery and manufacturing, aiming to replace traditional methods with more efficient solutions. The company's goal is to transform the production of biologics, making it faster and more cost-effective.

Company Size

51-200

Company Stage

IPO

Headquarters

Vancouver, Washington

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Absci's partnerships with AMD and Owkin enhance AI-driven drug discovery capabilities.
  • Generative AI collaborations with MSK and Twist Bioscience accelerate novel therapeutic development.
  • Increased adoption of AI and synthetic biology boosts Absci's innovative drug designs.

What critics are saying

  • Growing competition in AI-driven drug discovery may impact Absci's market share.
  • Dependence on partnerships could pose risks if collaborations don't yield results.
  • Rapid tech advancements could render Absci's current technologies obsolete.

What makes Absci unique

  • Absci uses AI and synthetic biology for novel protein-based drug discovery.
  • Their SoluPure method simplifies protein purification, reducing production time and costs.
  • Absci's high-throughput workflow generates active protein products in just three months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
GlobeNewswire
Jan 10th, 2025
Absci And Owkin Synergize Leading Techbio Platforms To Advance Generative Ai Drug Discovery

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.” Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids

Aitech365
Jan 9th, 2025
Absci & AMD Announce Collaboration to Boost AI Drug Discovery

Absci Founder & CEO Sean McClain will discuss the strategic partnership at the 43rd Annual J.P.Morgan Healthcare Conference on Wednesday January 15th at 4:30pm PT.

SiliconANGLE
Jan 8th, 2025
AMD invests $20M in Absci's AI drug discovery

AMD has invested $20 million in Absci Corp., an AI-driven drug discovery company. The partnership will see Absci shift some workloads to AMD's Instinct AI processors, enhancing its research capabilities. Absci will use the investment to improve its AI models and collaborate with AMD on developing new hardware and software for healthcare, focusing on drug discovery advancements.

GlobeNewswire
Jan 8th, 2025
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) - Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct(TM) accelerators and ROCm(TM) software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models.

247 Market News
Jan 8th, 2025
"Top Stocks Traders Are Buying Today: SANA, SYTA, CURR, EONR, and ABSI - Hot Picks Driving the Market"

Absci (NASDAQ: ABSI), a leader in AI-driven drug discovery, secured a $20 million strategic investment from Advanced Micro Devices (AMD).